Subscribe Past Issues Translate ▼

View this email in your browser



CSE: AIML OTCQB: AIMLF FWB: 42FB

The Pulse:

The Latest from AI/ML Innovations Inc.

04/12/25

In Case You Missed It:

- AIML granted US patent for its breakthrough ECG signal-processing neural network
- AIML begins a pilot at SickKids using MaxYield to enhance AI-driven ECG processing for early pediatric cardiac deterioration detection
- AIML signs commercial term sheet with Equimetrics to deploy tech in veterinary and equine cardiac monitoring platforms.
- AIML & Cornerstone Physiotherapy to pilot MaxYield™ and Insight360™ for cardiac performance testing of elite Hyrox athletes
- Cardiac Biomarkers Market to Surpass \$100 Billion by 2034

Past Issues

Translate >

Latest Allieuneements



Full Press Release

AIML has secured US Patent for its ECG signal-processing neural network technology, enhancing its intellectual property portfolio.

The patent protects the company's innovative ECG denoising and mapping technology that powers its MaxYield, Insight360 and CardioYield products.

Neural Cloud, an AIML subsidiary, has launched a pilot program at The Hospital for Sick Children (SickKids)

The initiative implements their MaxYield platform to process ECG signals for AI models, potentially enhancing early detection of cardiac deterioration in pediatric patients. The project is being led by Dr. Cedric Manlhiot and the Ted Rogers Centre.



Full Press Release



Neural Cloud has signed a commercial agreement with Equimetrics to deploy MaxYield™ and CardioYield™ technologies in veterinary and equine cardiac monitoring platforms.

Past Issues

Translate ▼

S-PRO product lines, expanding AIML's footprint into the global Equine & Veterinary markets

NeuralCloud and Cornerstone
Physiotherapy launch pilot testing
MaxYield™ and Insight360™
technologies on Hyrox athletes.

The collaboration utilizes 1-lead ECG enhancement for comprehensive cardiac performance assessment, delivering custom analytics reports focused on endurance and strength metrics.



Full Press Release

Must-Watch Interviews



Watch Full Interview

AI/ML Innovations Inc. CEO, Paul
Duffy, joins TraderTV Livestream for an
Interview

Paul walks through AIML's product suite, market opportunities, scalability, & early commercialization traction through our pilot programs

Past Issues

Translate >

depth Interview

Paul goes deep on the MaxYield &
CardioYield technology stack, recent patent
announcement, and regulatory (FDA, Health
Canada) progress



Watch Full Interview

Industry Watch



Read Full Report

Cardiac Biomarkers Outlook Report 2026:

- Cardiac biomarkers market projected to grow from USD 27.42B in 2025 to \$100.3B by 2034 (15.5% CAGR)
- Point-of-care testing enabling faster diagnostics in diverse settings
- AI-supported multi-biomarker platforms enhancing personalized risk assessment

Previous Newsletter

Past Issues

Translate >

Read more about our recent announcements & news in the previous issue of *The Pulse* from AI/ML Innovations Inc.



October Newsletter

About AI/ML Innovations Inc.

(CSE:AIML | OTCQB:AIMLF | FWB:42FB)

AIML deploys advanced AI and neural-network signal-processing to turn noisy biometric data - starting with ECG - into diagnostic-grade insight. Our flagship MaxYield™ platform, now in FDA 510(k) review, powers wearables and remotemonitoring systems worldwide. With recent pilot programs validating the technology & use case, AIML is scaling cloud-based ECG clarity for global healthcare & wellness for humans & animals.

Learn More About AIML







Subscribe	Past Issues		Translate ▼
		Our mailing address is:	
		Want to change how you receive these emails?	
		You can <u>update your preferences</u> or <u>unsubscribe</u>	